Full TitlePilot Study of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis Back to top
Monoclonal immunoglobulin deposition disease (MIDD — also known as Light Chain Deposition Disease, or LCDD) and amyloidosis are two rare conditions associated with abnormal plasma cells. The purpose of this study is to evaluate a treatment regimen that consists of the drugs bortezomib and dexamethasone, followed by a transplant of a patient’s own stem cells (autologous stem cell transplantation), and then another round of bortezomib and dexamethasone as maintenance therapy in patients with MIDD or amyloidosis.Back to top
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have MIDD/LCDD or amyloidosis.
- Patients may not have already been treated for the disease, with the exception of one cycle of dexamethasone.
- Patients may not have had prior treatment with bortezomib.
- At least 3 weeks must have passed since completion of any prior radiation therapy.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- Patients must be age 18 or older.